CRISPR Therapeutics Stock News

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

On Friday, the FDA approved CRISPR's Casgevy gene-editing treatment for sickle cell anemia. Analysts are mixed in their opinions on how big a deal this is for CRISPR.

CRISPR Therapeutics ( CRSP ) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old def

CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what

The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.

The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after

Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR

A gene-editing therapy for sickle cell disease was approved by US regulators, a milestone for the DNA-modifying technology Crispr. Crispr Co-Inventor, 2020 Nobel Prize winner in chemistry, and Innovat

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.

Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.

Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.

Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.

CRISPR Therapeutics could commercialize its first medicine in the U.S. very soon. Yet, it laid off a significant portion of its workforce in advance of that possibility.

The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.